Hyperfine, Inc. (HYPR) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Hyperfine, Inc.

HYPR

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

60M

Medical - Devices

Next Earning date - 14 Aug 2025

60M

Medical - Devices

Next Earning date - 14 Aug 2025

0.77USD

-0.04 ( -4.38%)

Market Closed (as of Jul 07, 20:00 EDT)

Relative Strenght

21

Volume Buzz

-92%

Earning Acce

No

Dist 52w H.

60%

Quote Panel

Updated July 8, 2025

1W 5.50 % 1M -1.19 % 3M 12.52 % 1Y -22.74 %

Key Metrics

Market Cap
59.55M
Shares Outstanding
77.84M
Share in Float
71.44M
Dividende
0

Earning Date
14 Aug 2025
Price Target
0.765
Average Volume
2.28M
Beta
0.946

Range
0.533-1.9
Industry
Medical - Devices
Website
https://hyperfine.io
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

5.08x

P/S Ratio

1.34x

P/B Ratio

0.0

Debt/Equity

-343.4%

Net Margin

$-0.5

EPS

How HYPR compares to sector?

P/E Ratio

Relative Strength

HYPR

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$18M

759%

2026-Revenue

$0.42

-248%

2026-EPS

$18M

-68%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

Jefferies

downgrade

Previous: Not converted

2024-05-14

Now: Hold

B. Riley

initialise

Previous: Not converted

2022-10-04

Now: Buy

Prescience Point

initialise

Previous: Not converted

2022-10-03

Now: Buy

Wells Fargo

downgrade

Previous: Not converted

2022-08-11

Now: Overweight

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.15
vs -0.33

Q3.23

N/A

-0.15
vs -0.19

Q4.23

N/A

-0.15
vs -0.19

Q1.24

N/A

-0.14
vs -0.17

Q2.24

N/A

-0.14
vs -0.15

Q3.24

N/A

-0.14
vs -0.15

Q4.24

N/A

-0.14
vs -0.15

Q1.25

N/A

-0.12
vs -0.14

Q2.25

N/A

-0.12
vs -0.14

Q3.25

N/A

-0.11
vs -0.14

Sales Growth

YoY

Current

Estimates

Q2.23

+121%

3.4M vs 1.5M

Q3.23

-1%

2.3M vs 2.3M

Q4.23

+89%

2.7M vs 1.4M

Q1.24

+25%

3.3M vs 2.6M

Q2.24

+7%

3.6M vs 3.4M

Q3.24

+56%

3.6M vs 2.3M

Q4.24

-14%

2.3M vs 2.7M

Q1.25

-35%

2.1M vs 3.3M

Q2.25

-17%

3M vs 3.6M

Q3.25

+11%

4M vs 3.6M

Return on Equity

QoQ

Q2.23

-10%

-0.10
vs -0.10

Q3.23

-11%

-0.11
vs -0.10

Q4.23

-13%

-0.13
vs -0.11

Q1.24

-13%

-0.13
vs -0.13

Q2.24

-15%

-0.15
vs -0.13

Q3.24

-18%

-0.18
vs -0.15

Q4.24

-21%

-0.21
vs -0.18

Q1.25

-22%

-0.22
vs -0.21

Institutionnal Ownership

QoQ

Q2.23

37

37
vs 35

6%

Q3.23

41

41
vs 37

11%

Q4.23

52

52
vs 41

27%

Q1.24

47

47
vs 52

-10%

Q2.24

44

44
vs 47

-6%

Q3.24

43

43
vs 44

-2%

Q4.24

39

39
vs 43

-9%

Q1.25

37

37
vs 39

-5%

Earnings Growth

Latest News

HYPR

businesswire.com

8 hours ago

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

HYPR

businesswire.com

9 hours ago

Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI

HYPR

businesswire.com

9 hours ago

Hyperfine Announces FDA Clearance of Optive AI™ Software, Introducing the Most Substantial Image Quality Improvement Ever for the Swoop® System

HYPR

zacks.com

13 hours ago

Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System

HYPR

zacks.com

18 hours ago

Hyperfine, Inc. (HYPR) Reports Q1 Loss, Lags Revenue Estimates

HYPR

seekingalpha.com

20 hours ago

Hyperfine, Inc. (HYPR) Q1 2025 Earnings Call Transcript